Prednisone

證據等級: L5

預測適應症: 10 個

Prednisone: From General Corticosteroid Therapy to Alopecia Areata

One-Sentence Summary

Prednisone is a synthetic glucocorticoid; this evidence pack does not have its original approved indication on file (the product is not currently marketed in Canada, and DrugBank MOA data was not returned). The TxGNN model predicts it may be effective for Alopecia Areata, a hypothesis reinforced by decades of existing off-label clinical practice — supported here by 32 clinical trials (mostly indirect autoimmune-mechanism analogs) and 20 publications, including one completed Phase 3 RCT that tested prednisone directly in severe alopecia areata.

Quick Overview

Item	Content
Original Indication	Not on file (no Health Canada license record for this product; general glucocorticoid/anti-inflammatory use only known from pharmacological class)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Canada Market Status	✗ Not Marketed (未上市)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for prednisone was not returned in this evidence pack (flagged as data gap DG002), and no original indication is on file because the product currently has no Canadian market authorization. Based on general pharmacological knowledge, prednisone is a synthetic glucocorticoid that suppresses immune-mediated and inflammatory processes — it inhibits pro-inflammatory cytokine transcription, reduces lymphocyte activation and proliferation, and dampens antigen-presenting cell activity. This broad immunosuppressive/anti-inflammatory action underlies its long-established use across autoimmune and inflammatory conditions generally.

Alopecia areata (AA) is a T-cell–mediated autoimmune attack on the hair follicle. Mechanistically, prednisone’s suppression of peri-follicular lymphocytic infiltration and cytokine release is directly relevant to this pathophysiology, and systemic corticosteroids (alone or combined with methotrexate) have in fact been used clinically for severe AA for decades — the literature evidence below dates back to 1956.

Importantly, this means the TxGNN signal is less a “novel” repurposing discovery and more a rediscovery/validation of established off-label practice. Contemporary high-quality trial activity for AA has largely shifted toward newer biologics and JAK inhibitors (baricitinib, VIB7734, etc.), with prednisone appearing mainly as a comparator/background therapy rather than the primary investigational agent — an important nuance for prioritization.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02037191	Phase 3	Completed	90	RCT: methotrexate alone vs. methotrexate + low-dose prednisone vs. placebo in severe AA (alopecia totalis/universalis/”grave pelade”). Only trial directly testing prednisone in this indication.
NCT02141672	Phase 2	Completed	265	Voclosporin vs. placebo for remission in active lupus nephritis. Graded B — same broad autoimmune category, different drug; not prednisone-specific.
NCT03021499	Phase 3	Completed	358	Voclosporin vs. placebo for renal response in lupus nephritis. Indirect autoimmune analog only.
NCT03843125	Phase 3	Terminated	1147	Long-term safety/efficacy of baricitinib in SLE; study terminated early. Indirect analog.
NCT04058028	Phase 2	Completed	244	Dose-ranging study of rozibafusp alfa in SLE with inadequate response to standard care. Indirect analog.
NCT04925934	Phase 2	Completed	214	VIB7734 vs. placebo in moderate-to-severe SLE. Indirect analog, not prednisone.
NCT03845517	Phase 2	Completed	350	PF-06700841 dose-ranging study in active SLE. Indirect analog.
NCT02975336	Phase 2	Terminated	469	M2951 dose-ranging study in SLE; terminated. Indirect analog.
NCT02437890	Phase 2	Completed	312	ALX-0061 (subcutaneous) dose-ranging study in SLE, includes a steroid-reduction endpoint. Indirect analog.
NCT04835441	Phase 2	Completed	76	Acazicolcept (ALPN-101) vs. placebo in moderate-to-severe SLE. Indirect analog.

Note: Of the 32 trials returned for this drug–disease query, only NCT02037191 tests prednisone directly in alopecia areata; the remaining B/C-graded trials were retrieved via broader autoimmune-disease association and test unrelated investigational drugs (largely for SLE/lupus nephritis, not AA itself).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36884234	2023	RCT	JAMA Dermatology	2-step double-blind RCT: methotrexate alone vs. methotrexate + low-dose prednisone in alopecia totalis/universalis; combination improved hair regrowth over methotrexate alone.
1444509	1992	Review	Archives of Dermatology	Comprehensive review of AA therapies (including corticosteroids); notes efficacy/safety data are difficult to compare across heterogeneous studies.
4571041	1973	Cohort	Archives of Dermatology	Immunologic studies in AA with prednisone treatment — early evidence supporting immune-mediated pathogenesis and steroid responsiveness.
791152	1976	Case Series	Archives of Dermatology	Follow-up of 18 AA patients on alternate-day prednisone: initial response often not durable long-term; notable steroid-related side effects.
911178	1977	Case Series	Archives of Dermatology	Reports clinical outcomes of prednisone therapy for alopecia areata.
26735937	2016	Cohort	Dermatology (Basel)	Methotrexate combined with low-to-moderate dose corticosteroids evaluated for efficacy/safety in severe AA.
37467740	2023	Case Series	Clinical and Experimental Dermatology	8-case series: baricitinib + low-dose corticosteroids produced major improvement in very severe AA (SALT ≥95) after baricitinib or methotrexate alone had failed.
13368875	1956	Case Series	Medical Times	Early historical report of AA (partialis/totalis) treated with cortisone, hydrocortisone, prednisone, and prednisolone.
38650498	2024	Cohort	Italian Journal of Dermatology and Venereology	Real-world characterization of hospitalized AA patients in Italy — comorbidities, treatment patterns, economic burden.
16019495	2005	Case Report	Leukemia & Lymphoma	Case of AA with multifocal bone involvement in a young adult, later diagnosed with Hodgkin’s disease.

Canada Market Information

Prednisone currently holds no marketing authorization (DIN) in Canada for this product record — taiwan_regulatory.total_licenses = 0 and the license list is empty. No product-level dosage form or approved-indication text is available from this data source.

Other Candidate Indications From This Evidence Pack (Context)

TxGNN returned 10 alopecia/immune-related high-score predictions for prednisone. Beyond the primary candidate above, the table below summarizes the rest for transparency — most are assessed as low-confidence noise or already-established use, not new repurposing opportunities:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation	Note
2	Alopecia mucinosa	99.99%	L4	Research Question	Follicular mucinosis can be idiopathic or malignancy-associated; malignancy must be excluded before considering steroids.
3	Telogen effluvium	99.99%	L5	Hold	Typically non-immune/reactive hair loss; mechanistic link to corticosteroids is weak — likely false positive.
4	Quinquaud’s folliculitis decalvans	99.99%	L5	Hold	Primarily bacteria-driven scarring folliculitis; antibiotics are first-line, steroids only adjunctive.
5	Alopecia antibody deficiency	99.99%	L5	Hold	No direct evidence; only a broad “autoimmune comorbidity” inference.
6	Hereditary hypotrichosis with recurrent skin vesicles	99.99%	L5	Hold	Monogenic follicular development disorder; no plausible steroid target.
7	Alopecia-intellectual disability-hypogonadism syndrome	99.99%	L5	Hold	Rare genetic syndrome; no supporting evidence.
8	Atrichia with papular lesions	99.95%	L5	Hold	HR-gene structural defect (non-inflammatory); no supporting evidence.
9	Tenosynovitis	99.80%	L2	Proceed with Guardrails	Prednisone is already standard therapy for RA/PMR/ICI-induced inflammatory tenosynovitis — this reflects established practice, not a novel repurposing signal.
10	Prolapse of lacrimal gland	99.66%	L5	Hold	Anatomic/mechanical condition typically requiring surgery; no mechanistic or evidentiary support.

Interpretation: Only ranks 1 and 9 clear the bar for “Proceed with Guardrails,” and both represent confirmation of long-standing clinical practice rather than a new hypothesis. Ranks 2–8 and 10 should be treated as low-priority/likely knowledge-graph noise pending further evidence.

Safety Considerations

Please refer to the package insert for safety information. (This evidence pack’s key warnings, contraindications, and drug-interaction fields returned no usable data — the TFDA/Health Canada label review is flagged as a Blocking data gap (DG001) and must be resolved before any S1 safety screening.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed Phase 3 RCT (NCT02037191) directly tested prednisone (combined with methotrexate) in severe alopecia areata, and this is corroborated by a multi-decade body of case series/cohort literature (1956–2024) showing biological plausibility and real-world use. However, this is best framed as validating existing off-label practice rather than a novel discovery, current standard-of-care trends favor newer JAK inhibitors/biologics, and this specific product record has no Canadian market authorization or safety-label data on file.

To proceed, the following is needed:

TFDA/Health Canada product label — warnings and contraindications (currently a Blocking gap, DG001)
Confirmed mechanism-of-action reference via DrugBank API (DG002)
Clarification of the drug’s original/approved indication (no license or indication text is currently on file for this Canadian market record)
Drug interaction (DDI) screening — current query status is “not_found”
Dermatology specialist input weighing prednisone against current first-line AA options (e.g., JAK inhibitors) given the evolving standard of care
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.